Your browser doesn't support javascript.
loading
Prognostic Impact of Anemia in Patients Undergoing Aortic Valve Replacement: A Nationwide Study.
Brems, Daniel Alexander; Petersen, Jeppe Kofoed; Begun, Xenia; Smerup, Morten; Butt, Jawad Haider; Køber, Lars; Fosbøl, Emil.
Afiliación
  • Brems DA; Department of Cardiology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
  • Petersen JK; Department of Cardiology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
  • Begun X; Department of Cardiology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
  • Smerup M; Department of Cardiothoracic Surgery, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
  • Butt JH; Department of Cardiology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
  • Køber L; Department of Cardiology, Zealand University Hospital, Roskilde, Denmark.
  • Fosbøl E; Department of Cardiology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
Article en En | MEDLINE | ID: mdl-38986512
ABSTRACT

BACKGROUND:

Patients undergoing aortic valve replacement (AVR) have high readmission rates. Several risk factors have been proposed as potential modifiable targets, including anemia. We examined the association between anemia at discharge and subsequent outcomes in these patients.

METHODS:

Using Danish nationwide registries, we identified all patients who underwent AVR between 2015-2021, were alive at discharge (index date), and had an available hemoglobin (Hb) measurement taken between procedure and discharge. Patients were categorized as having i) moderate/severe anemia (Hb<6.2 mmol/L) or ii) no/mild anemia (Hb≥6.2 mmol). The one-year rates of all-cause mortality, all-cause hospital admission, heart failure (HF) admission, and atrial fibrillation (AF) admission were compared using multivariable Cox regression models.

RESULTS:

8,614 patients were identified; 2,847 (33.1%) had moderate/severe anemia (60.2% male, median age 74) and 5,767 (66.9%) had no/mild anemia (68.0% male, median age 76). For these two groups, respectively, the cumulative one-year incidences of the outcomes were i) all-cause mortality 5.1% vs. 4.3%; ii) all-cause admission 53.8% vs. 47.5%; iii) AF admission 14.0% vs. 11.6%); iv) HF admission 6.8% vs. 6.2%. In adjusted analysis, moderate/severe anemia, compared with no/mild anemia, was associated with higher rates of all-cause mortality (hazard ratio (HR) 1.27 [95%CI 1.02-1.58]), all-cause admission (HR 1.22 [95%CI 1.14-1.30]), and AF admission (HR 1.23 [95%CI 1.08-1.40]), but not HF admission (HR 1.09 [95%CI 0.91-1.31]).

CONCLUSION:

In patients undergoing AVR, moderate/severe anemia at discharge, compared with no/mild anemia, was associated with increased all-cause mortality, all-cause hospital admission, and AF admission, but not HF admission, at one-year post-discharge.
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Eur Heart J Qual Care Clin Outcomes Año: 2024 Tipo del documento: Article País de afiliación: Dinamarca

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Eur Heart J Qual Care Clin Outcomes Año: 2024 Tipo del documento: Article País de afiliación: Dinamarca